Meeting
2021 ASCO Annual Meeting
Whole-exome sequencing in advanced-stage sensitizing EGFR mutation non-small cell lung cancer: Explore resistance biomarkers to EGFR TKI treatment.
Authors
Chanida Vinayanuwattikun
Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Chanida Vinayanuwattikun , Piyada Sitthideatphaiboon , Chinachote Teerapakpinyo , Krittiya Korphaisarn , Naravat Poungvarin , Poonchavist Chantranuwatana , Shanop Shuangshoti , Chatchawit Aporntewan , Virote Sriuranpong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9039)
DOI
10.1200/JCO.2021.39.15_suppl.9039
Abstract #
9039
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients.
First Author: Collin M. Blakely
Poster
2023 ASCO Annual Meeting
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
First Author: Laurien Joanna Zeverijn
Poster
2021 ASCO Annual Meeting
A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Liu Li
Poster
2018 ASCO Annual Meeting
Real-time circulating tumor DNA profiling of advanced cholangiocarcinoma (CCA).
First Author: Kabir Mody